TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03473106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet use
Description: Surgery requiring a pneumatic tourniquet on the thigh
Study: NCT00165750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONEPEZIL HYDROCHLORIDE
Description: One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
Study: NCT03496350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Culturally adapted transdiagnostic internet-delivered CBT in Arabic
Study: NCT03351816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation of atrial fibrillation
Description: Pulmonary vein isolation by radiofrequency or cryoablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioversion
Description: External electric shock delivery under general anesthesia.
Study: NCT02154620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plate
Description: An anatomically countoured volar plate is implanted through a Henry's incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes TCP volar plate
Study: NCT02810301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic ES1
Description: B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
Study: NCT01904916

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histological biopsy procedure
Study: NCT02995083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Description: Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 ml
Description: Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Air 10 ml
Description: Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
Study: NCT02974335

Intervention type: BEHAVIORAL
Intervention: Interviews with Stakeholders
Description: The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.

Intervention type: BEHAVIORAL
Intervention: Interviews with Stakeholders
Description: The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.

Intervention type: BEHAVIORAL
Intervention: Interviews with Stakeholders
Description: The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
Study: NCT01613989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic hip surgery, operated under manual control
Description: : Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic hip surgery operated under navigation based on EOS imaging
Description: The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
Study: NCT04532593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous adipose stem cell injection
Description: Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline will be injected underneath skin graft (0.05 ml/cm2).
Study: NCT02109432

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Directed Pedal Desk
Description: participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facilitated Pedal Desk
Description: participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facilitated Pedal Desk with Pedometer
Description: participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
Study: NCT02554812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: OX40 Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: OX40 Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: Anti-M-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: Anti-M-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: TLR9 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: TLR9 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: TLR9 agonist
Study: NCT03793231

Intervention type: COMBINATION_PRODUCT
Intervention: fungalAi platform technology
Description: Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.

Intervention type: COMBINATION_PRODUCT
Intervention: fungalAi platform technology
Description: Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
Study: NCT03409406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Intervention
Description: This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
Study: NCT02573129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Meat Rich
Description: Mediterranean diet rich in red meat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Meat Rich
Description: Mediterranean diet rich in red meat
Study: NCT01070693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open mesh inguinal hernia repair
Description: Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open mesh inguinal hernia repair
Description: Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Description: Prolene Hernia System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Description: Lichtenstein technique
Study: NCT01949623

Intervention type: OTHER
Intervention: Anterior Chamber (AC) tap
Description: Aqueous Samples will be collected for measurement of biomarkers

Intervention type: OTHER
Intervention: Anterior Chamber (AC) tap
Description: Aqueous Samples will be collected for measurement of biomarkers
Study: NCT00446953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Description: 2x12 mg betamethazone c-section at 38 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: c-section at 39 weeks
Study: NCT02152059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
Study: NCT00770042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg qd for 5 days (Days 2-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythomycin
Description: Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 50 mg on Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 50 mg on Days 1 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 200mg Days 1 and 6
Study: NCT02789670

Intervention type: OTHER
Intervention: Blood sample collection
Description: Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group

Intervention type: OTHER
Intervention: Blood sample collection
Description: Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
Study: NCT04397913

Intervention type: DRUG
Intervention: Paracetamol
Description: 15 mg/kg, q6h

Intervention type: DRUG
Intervention: Ibuprofen
Description: 10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
Study: NCT00902018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: healthy controls
Description: single blood draw for all measures included in the intervention arms
Study: NCT04579302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior block (SAB)
Description: Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline (as a placebo)
Description: Patients will receive a sham block with 20 ml saline (as a placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine
Study: NCT04686760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: 2 mg/ml solution of nitroglycerin used for nebulization four hourly
Study: NCT01529580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Verbal School Aged Children with Autism (NVSACA) Intervention
Description: The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Verbal School Aged Children with Autism (NVSACA) Intervention
Description: The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Verbal School Aged Children with Autism (NVSACA) Intervention
Description: The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training.
Study: NCT00686322

Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
Description: Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Study: NCT00101816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
Study: NCT03826836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
Study: NCT01413620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopheryl acetate
Description: Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
Study: NCT01119833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1070
Description: Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
Study: NCT03865667

Intervention type: DEVICE
Intervention: PROFEMUR® Preserve Femoral Stem
Description: Total Hip Total Hip Arthroscopy
Study: NCT03409406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ST Intervention
Description: This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
Study: NCT04679857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TKA
Description: Total Knee Arthroplasty
Study: NCT03409406

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ST Intervention
Description: This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
Study: NCT03131050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intramuscular injection with saline (1ml, QD or Bid) during the first three days;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
Study: NCT03736317

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TBS
Description: Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real mPFC cTBS
Description: Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real dlPFC iTBS
Description: Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real dlPFC iTBS + real mPFC cTBS
Description: Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
Study: NCT02854735

Intervention type: OTHER
Intervention: Imaging by CT and densitometry
Description: Imaging by CT and densitometry, no intervention involved
Study: NCT01580189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 18g protein, immediately after training, 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate milk
Description: 500ml chocolate milk, immediately after training, 9 weeks
Study: NCT04679857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKA
Description: Total Knee Arthroplasty
Study: NCT02252185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Johnson&Johnson Medical Suzhou made Spine Fusion System
Description: interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imported EXPEDIUM screws and OPAL cage
Description: Comparator in this study is active comparator.
Study: NCT02825966

Intervention type: DEVICE
Group type: OTHER
Intervention: AUDICOR then LifeVest then AUDICOR
Description: Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
Study: NCT02274272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADR-1
Description: two ADR-1 capsules, once daily, QD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-263
Description: two GMNL-263 capsules, once daily, QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two placebo capsules, once daily, QD
Study: NCT03054805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYAIRI-BM
Description: MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
Study: NCT00832130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mini System
Description: In-office device treatment for meibomian gland dysfunction by a physician

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Mini System
Description: In-office device treatment for meibomian gland dysfunction by a physician

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iHeat Portable Warm Compress Therapy
Description: At-home daily warm compress therapy
Study: NCT02460783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost (R) 5-2 diet
Description: Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Diet
Description: Counseling and educational material on diet portion, consistency